204
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab

ORCID Icon, , , , , ORCID Icon, & ORCID Icon show all
Pages 1583-1587 | Received 12 Dec 2022, Accepted 24 May 2023, Published online: 12 Jun 2023
 

Acknowledgements

This study was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748.

Disclosure statement

AM receives research funding from Incyte Corporation and Amryt Pharma; consults for ADC Therapeutics, Alira Health, Protagonist Therapeutics, OnQuality, and Janssen; and receives royalties from UpToDate. MBG receives research funding from Amgen, Actinium Pharmaceuticals, and Sanofi and has served in an advisory/consulting role for Sanofi, Novartis, and Allogene. ACK has received advisory/consulting fees from: Astellas and Blueprint Medicines. RP, SG, SD, MP, and EC have no conflicts of interest to disclose.

Data availability statement

Data are available within the article or its supplementary materials.

Additional information

Funding

This study was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.